Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
Los Bonos 1, 2 y 3 se encuentran actualmente cerrados. En las próximas semanas se proporcionará más información acerca de su apertura de cara a 2025.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
105
resultados
Última actualización
20/12/2024 [08:22:00]
Resumen de: AU2023281045A1
Methods, compositions, and systems for treating various cancers are disclosed. The disclosed compositions may include a polypeptide with affinity for a CD99 cell surface protein. Disclosed polypeptides may comprise a sequence selected from GYYMH, RINPYTGATTYNQIFKD, YYYGNNYNVYLDY, SASQGISNYLS, YTSTLHS, and QQYSNLPWT, and may include mouse, human, or humanized peptide sequences. In many embodiments, the polypeptides may be immunoglobulins, for example IgG3 or IgG4. The disclosed polypeptides may be administered to a subject having a cancer cell with elevated expression of CD99. In some embodiments, the subject may be suffering from cancer, including diffuse intrinsic pontine glioma (DIPG), Ewing Sarcoma, acute myeloid leukemia (AML), ependymoma, or neuroblastoma. Treatment methods include administering the disclosed polypeptides to a subject that may also be treated with radiation. Disclosed herein are systems for treating one or more cancers. The systems may comprise a radiation source, for example a medical fractionated radiation source.
Resumen de: US2024415960A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering therapeutically effective amounts of a BCMA×CD3 bispecific antibody and a GPRC5D×CD3 bispecific antibody to the subject.
Resumen de: US2024415888A1
The present technology provides anti-Thyroid Stimulating Hormone Receptor (TSHR) multi-specific (e.g., bispecific) immunoglobulin-related compositions and methods of using the same to treat TSHR-associated pathologies including, but not limited to, thyroid cancers, T-ALL (T lineage acute lymphoblastic leukemia), multiple myeloma and Grave's disease. Kits for use in practicing the methods are also provided.
Resumen de: US2024417420A1
CD33 ligands which are useful for the synthesis of CD33 ligand-bearing carriers, wherein said CD33 ligand-bearing carriers are directly or indirectly linked to or associated with at least one anti-cancer agent, are described herein. Uses of said CD33 ligand-bearing carriers for treating and/or preventing a disease, disorder, or condition such as acute myeloid leukemia (AML) are also described.
Resumen de: US2024418722A1
Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice.Spleens from mice immunized against sheep red blood cells (SRBC) were fused to an 8-azaguanine-resistant clone (X63-Ag8) of MOPC 21 myeloma. Over 50% of the derived hybrid lines produce and secrete immunoglobulins different from the MOPC 21 myeloma. About 10% of the hybrid lines exhibit anti-SRBC activity. The high proportion of antibody-producing hybrids suggests that the fusion involves a restricted fraction of the spleen cell population, probably cells committed to antibody production.In order to avoid the presence of the MOPC 21 heavy chain in the specific hybrids, another myeloma cell line (NSI/Ag4-1) has been used. This is a nonsecreting variant of the MOPC 21 myeloma which does not express heavy chains.Three anti-SRBC (probably of the μ, γ2b and γ1 classes, respectively) and two anti-2,4,6-trinitrophenyl (of the μ class antibody-producing hybrids have been repeatedly cloned. By random selection and by selection of specific clones according to their lytic activity (clone plaque selection), a number of different lines have been constructed. Such lines express different combinations of the four possible chains of each hybrid line: the myeloma γ and k chains and the specific antibody heavy and light chains. In three cases (Sp1
Resumen de: US2024417388A1
The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity:wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
Resumen de: AU2023271953A1
The present disclosure relates to improved methods of treatment with nirogacestat. The present invention further includes improvement methods of treating conditions responsive to inhibition of gamma secretase, such as desmoid tumor, multiple myeloma, ovarian granulosa cell tumors, with nirogacestat and pharmaceutically acceptable salts thereof.
Resumen de: US2024418729A1
Some pathological conditions are accompanied by the increase in dimers of free light chains (FLCs) kappa and/or lambda. For instance, high levels of FLC dimers are found in AL amyloidosis, multiple myeloma, and multiple sclerosis. There is thus a need for sensitive methods that could specifically and quantitatively measure the amount of FLC dimers in a sample. The present application relates to a method for detecting and quantifying immunoglobulin FLC dimers in a sample that comprises subjecting the sample to proteolytic digestion under non-reducing conditions and subjecting the digested sample to mass spectrometry analysis to detect immunoglobulin free light chain dimer peptides. The method may be useful for diagnosis and monitoring of diseases characterized by the aberrant production of FLCs, such as plasma cell discrasias. Light-chain deposition disease (LCDD), autoimmune diseases, chronic kidney disease (CKD), and inflammatory conditions.
Resumen de: US2024417472A1
The disclosure relates to methods of treating non-small cell lung cancer (NSCLC) or classical Hodgkin's Lymphoma (cHL) by administering a bispecific antibody, that binds to Programmed Death-1 (PD-1) and T-cell immunoglobulin and mucin domain containing protein-3 (TIM-3), to a subject with NSCLC or cHL in an amount from about 70 mg to about 1500 mg.
Resumen de: US2024417460A1
The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic anti bodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
Resumen de: US2024417404A1
Described herein is N-4-4-(4-morpholinyl)-7H-pyrrolo2,3-dpyrimidin-6-ylphenyl-4-3(R)-(1-oxo-2-propen-1-yl)amino-1-piperidinylmethyl-2-pyridinecarboxamide (Compound A) (Formula I),including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
Resumen de: US2024417405A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
Resumen de: AU2023218995A1
The present disclosure is directed to methods of genetically subtyping peripheral t-cell lymphoma.
Resumen de: WO2023152204A1
The present invention provides antibodies for the treatment of chronic lymphocytic leukemia (CLL). These antibodies target the B-cell receptor (BCR) of CLL cells characterised by R110-mutated immunoglobulin lambda variable 3-21 (IGLV3-21R110). The invention also provides nucleic acid sequences encoding the forgoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Resumen de: US2024408250A1
Methods for treating a proliferative disease in hematologic malignancy in a subject having a complex karyotype by administering an effective amount of an immunotherapy which includes a targeting agent for an epitope of CD33. The proliferative disease may be a hematological disease or disorder such as multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm. The effective amount of the anti-CD33 targeting agent may be an amount sufficient to induce myeloconditioning or an amount to induce myeloablation. The methods may further include transplanting allogeneic stem cells to the patient after administration of the anti-CD33 targeting agent.
Resumen de: WO2024250668A1
Disclosed in the present invention are a CLL1-CAR-T cell, and a preparation method therefor and the use thereof. The CLL1-CAR-T cell contains a chimeric antigen receptor, wherein the chimeric antigen receptor comprises a single domain antibody, a hinge region, a transmembrane region and an intracellular signaling region, and the single domain antibody has an amino acid sequence of positions 22-150 of SEQ ID No. 1. The CLL1-VHH-1 CAR-T cell of the present invention can secrete T cell specific effector molecule IFN-γ to specifically kill CLL1+ target cells, inhibit the proliferation of tumor cells in mice, prolong the survival time of mice, and can be used for immunotherapy of diseases associated with CLL1 target (such as acute myelogenous leukemia).
Resumen de: WO2024254507A2
Provided herein are, among other things, methods for treatment of B Cell Lymphomas with NK cells and a CD20 targeted antibody.
Resumen de: AU2023281205A1
The invention provides a CD16a-binding polypeptide which comprises at least one motif that binds to CD16a, wherein said polypeptide comprises the following structure: N-terminal portion-Helix 1-Separating portion-Helix 2-C-terminal portion the CD16a-binding motif being the portion Helix 1-Separating portion- Helix 2. The invention further provides pharmaceutical compositions comprising the CD16a- binding polypeptide, and the use of the CD16a-binding polypeptide or pharmaceutical compositions as a medicament, particularly for use in the treatment or prophylaxis of cancers such as multiple myeloma.
Resumen de: WO2024251884A1
The disclosure relates to multispecific binding proteins comprising a first and a second antigen binding domains (ABDs) and a cytokine moiety, wherein the first ABD binds specifically to human CD20 and the second ABD bind specifically to human NKp46, for use in treating refractory and/or relapsed B-cell non Hodgkin lymphoma.
Resumen de: WO2024254455A1
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell- like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).
Resumen de: US2024409641A1
The present disclosure provides multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR, pharmaceutical preparations and use of such multi-specific binding moieties and/or immunoglobulins in the treatment of a myelodysplastic syndrome.
Resumen de: US2024409545A1
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo3,4-dpyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Resumen de: US2024409558A1
Disclosed herein are heterocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia, lung cancer, colorectal cancer, pancreatic cancer, and other diseases or conditions dependent on KRas interaction.
Resumen de: US2024410017A1
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having multiple myeloma (MM). For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) having MM is likely to develop one or more therapy-related myeloid neoplasms (t-MNs) are provided. This document also relates to methods and materials for treating a mammal (e.g., a human) having MM where the treatment is selected based, at least in part, on whether or not the mammal is likely to develop one or more t-MNs.
Nº publicación: US2024408204A1 12/12/2024
Solicitante:
UNIV CALIFORNIA [US]
The Regents of the University of California
Resumen de: US2024408204A1
Compositions and methods are provided for treating lymphoma in an individual by targeting engineered phagocytes to lymphoma cells. In particular, the phagocytes provided for administration to an individual, who has lymphoma, are engineered to express a chimeric antigen receptor (CAR) that specifically binds to an antigen present on lymphoma cells. The CAR localizes the engineered phagocytes to sites where lymphoma cells are present. In some embodiments, phagocytic activity of the phagocytes is enhanced by further engineering the phagocytes to express a hyperactive Rac GTPase.
BOPI
Sede Electrónica
